Repositioning Candidate Details

Candidate ID: R0216
Source ID: DB00613
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Amodiaquine
Synonyms: Amodiaquine
Molecular Formula: C20H22ClN3O
SMILES: CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1
Structure:
DrugBank Description: A 4-aminoquinoquinoline compound with anti-inflammatory properties.
CAS Number: 86-42-0
Molecular Weight: 355.861
DrugBank Indication: For treatment of acute malarial attacks in non-immune subjects.
DrugBank Pharmacology: Amodiaquine, a 4-aminoquinoline similar to chloroquine in structure and activity, has been used as both an antimalarial and an anti-inflammatory agent for more than 40 years. Amodiaquine is at least as effective as chloroquine, and is effective against some chloroquine-resistant strains, although resistance to amodiaquine has been reported. The mode of action of amodiaquine has not yet been determined. 4-Aminoquinolines depress cardiac muscle, impair cardiac conductivity, and produce vasodilatation with resultant hypotension. They depress respiration and cause diplopia, dizziness and nausea.
DrugBank MoA: The mechanism of plasmodicidal action of amodiaquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. The drug binds the free heme preventing the parasite from converting it to a form less toxic. This drug-heme complex is toxic and disrupts membrane function.
Targets: Fe(II)-protoporphyrin IX binder; Histamine N-methyltransferase inhibitor
Inclusion Criteria: Therapeutic strategy associated